Skye Bioscience, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
SKYE$0.84+21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
CONSOLIDATED BALANCE SHEETS
| December 31 | ||
|---|---|---|
| ASSETS | 2025 | 2024 |
| Current assets | ||
| Cash and cash equivalents | $5,882,498 | $68,415,741 |
| Short-term investments | 19,854,723 | — |
| Prepaid expenses | 504,890 | 201,962 |
| Other current assets | 852,036 | 2,209,544 |
| Total current assets | 27,094,147 | 70,827,247 |
| Property and equipment, net | 898,930 | 1,432,752 |
| Operating lease right-of-use asset | 266,646 | 449,864 |
| Other assets | 53,910 | 53,910 |
| Total assets | $28,313,633 | $72,763,773 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $2,033,431 | $569,252 |
| Accrued payroll liabilities | 1,269,474 | 1,114,255 |
| Other current liabilities | 2,643,840 | 654,201 |
| Estimate for accrued legal contingencies and related expenses | 2,069,067 | 1,818,751 |
| Operating lease liability, current portion | 189,647 | 182,428 |
| Total current liabilities | 8,205,459 | 4,338,887 |
| Non-current liabilities | ||
| Operating lease liability, net of current portion | 83,999 | 273,162 |
| Total liabilities | 8,289,458 | 4,612,049 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 200,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024, respectively; 33,378,139 and 30,974,559 shares issued and outstanding at December 31, 2025 and 2024, respectively | 33,379 | 30,975 |
| Additional paid-in-capital | 206,865,282 | 199,070,421 |
| Accumulated deficit | (186,874,486) | (130,949,672) |
| Total stockholders’ equity | 20,024,175 | 68,151,724 |
| Total liabilities and stockholders’ equity | $28,313,633 | $72,763,773 |
| See accompanying notes to the consolidated financial statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.